Vertex Pharmaceuticals Incorporated (LON:0QZU)

London flag London · Delayed Price · Currency is GBP · Price in USD
466.98
-6.44 (-1.36%)
At close: Jul 25, 2025
-1.36%
Market Cap89.59B
Revenue (ttm)8.59B
Net Income (ttm)-765.40M
Shares Outn/a
EPS (ttm)-2.97
PE Ration/a
Forward PE24.19
Dividendn/a
Ex-Dividend Daten/a
Volume265
Average Volume237
Open474.65
Previous Close473.42
Day's Range466.98 - 474.65
52-Week Range378.12 - 519.68
Beta0.41
RSI48.72
Earnings DateAug 4, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1989
Employees 6,100
Stock Exchange London Stock Exchange
Ticker Symbol 0QZU
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 10 years by 1.83% on an annualized basis producing an average annual return of 13.39%. Currently, Vertex Pharmaceutical...

14 days ago - Benzinga

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis (CF) medic...

18 days ago - Business Wire

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health...

18 days ago - Business Wire

Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals . Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 11 trades. If w...

21 days ago - Benzinga

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term dat...

23 days ago - Seeking Alpha

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The compa...

24 days ago - Business Wire

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

24 days ago - CNBC

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

4 weeks ago - Reuters

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment ...

4 weeks ago - Business Wire

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 13.32%. Currently, Vertex Pharmaceutical...

4 weeks ago - Benzinga

Vertex Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ: VRTX). And retail traders should know. We noticed this today when the trades showed up on publicl...

5 weeks ago - Benzinga

Revenues at cystic fibrosis drugmaker Vertex hit $2.63bn on back of Kaftrio sales

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (2.26bn) last year.

5 weeks ago - Independent Ireland

Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

Ono and Vertex have entered into an exclusive collaboration and license agreement for povetacicept in Japan and South Korea Povetacicept is a therapeutic in development for multiple serious B cell-med...

5 weeks ago - Benzinga

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agre...

5 weeks ago - Business Wire

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORW...

6 weeks ago - Business Wire

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ETCompany...

7 weeks ago - Seeking Alpha

$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an average annual return of 13.76%. Currently, Vertex Pharmaceutical...

7 weeks ago - Benzinga

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potentia...

7 weeks ago - Benzinga

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with ...

2 months ago - Business Wire

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...

2 months ago - Seeking Alpha

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceutica...

2 months ago - Benzinga